Background:
Introduction
Inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), are idiopathic chronic relapsing inflammatory conditions of the gastrointestinal tract. Although the precise etiologies of IBD are not known, both diseases are thought to result from dysregulation of the host immune response to commensal intestinal flora in genetically predisposed persons. The north-south gradient of IBD prevalence, its epidemiology, the genetic association of vitamin D receptor polymorphisms, and the many physiological studies of the effects of vitamin D on the immune system and mucosal barrier function suggest that vitamin D plays an important role in the pathogenesis of IBD [1] [2] [3] .
Moreover, recent clinical evidence shows that vitamin D has promising clinical effects on disease activity, bone health, cancer prevention and depression. Therefore, we conducted a non-systematic review of published and in press articles, including reviews, meta-analyses, original studies, clinical trials and abstracts from scientific meetings to the extent that they were identified in the PubMed, Scopus, MEDLINE or GoogleScholar. The search terms included 'vitamin D' and 'Crohn's disease' or 'ulcerative colitis'. This review aims to explore the therapeutic potential of vitamin D in patients with CD and/or UC. Furthermore, based on current available evidence, we discuss the optimal target serum concentration, dosing, pharmacologic form and route of vitamin D supplementation.
Vitamin D Vitamin D physiology
Vitamin D is a group of fat-soluble secosteroids with several hormonal functions in the human body. The physiology of vitamin D has been thoroughly reviewed 4 . The roles of vitamin D in calcium metabolism and healthy bone development have been recognised for more than a century. However, the discovery of the vitamin D receptor (VDR) in most tissues and cells of the body has provided new insights into the non-calcaemic functions of vitamin D, including cell proliferation, immunomodulation and cell differentiation [5] [6] [7] .
The effects of vitamin D on the immune system are complex. Vitamin D receptor is abundantly expressed on immune cells, especially on activated T lymphocytes and dendritic cells. Vitamin D receptor is also expressed on antigen presenting cells, monocytes, macrophages, cytotoxic NK cells, and T and B lymphocytes 7 8 . Vitamin D has been shown to stimulate the production of T-regulatory lymphocytes and the expression of interleukin (IL)-4, IL-10 and transforming growth factor (TGF)-β, to inhibit the differentiation of CD4+ T lymphocytes into Th1 cells, and to suppress the effector functions of the latter 6 9 . These 10 . Vitamin D has also been associated with increased risks of infectious diseases, malignancies, transplant rejection and cardiovascular disease 11 . An overview of vitamin D sources, metabolism and effects on imunne system is outlined in Figure 1 .
Figure 1

Vitamin D deficiency
Modern lifestyles appear to result in widespread vitamin D deficiency (~60%), especially at the end of winter 12 13 . The production of vitamin D3 depends on exposure to sunshine, the season of the year, latitude, clothing, skin pigmentation and the use of sunscreen. The intake of vitamin D in a typical western diet is limited (~40-100 IU/day) [13] [14] [15] . Therefore, a sundeprived lifestyle is a major factor associated with vitamin D insufficiency.
Pre-clinical data linking vitamin D to IBD
Accumulating evidence from epidemiological, genetic, animal and in vitro studies has linked vitamin D to IBD (Table 1) 4 .
Epidemiology
Epidemiologic studies have shown that vitamin D deficiency is highly prevalent among patients with IBD [16] [17] [18] [19] . For example, vitamin D deficiency (<20 ng/ml) has been reported in 18-50% of patients with IBD at the end of summer and in 50-68% at the end of winter, with an additional ~35% of patients being vitamin D insufficient (20-29.9 ng/ml) 16 44 .
A third epidemiological investigation found that serum concentrations of vitamin D were lowest after winter 22 25 . This correlates with seasonal patterns in the incidence and flares of IBD, which peak during the spring season [45] [46] [47] [48] [49] .
Lastly, smoking is a well recognised risk factor for CD and several studies have observed that smokers have lower vitamin D levels than non-smokers 18 50-52 . 55 .
Genetic studies
Animal models
A c c e p t e d M a n u s c r i p t 58 60 .
Mechanistically, these mice had reduced numbers of CD8alphaalpha intraepithelial lymphocytes, low levels of IL-10 and showed increased inflammatory responses to normally harmless commensal flora 61 . Furthermore, vitamin D was shown to inhibit several TNFalpha-related genes in these animal models 62 .
The findings in IL-10 KO mice were confirmed in dextrane sulphate sodium (DSS) and TNBS-induced colitis models [63] [64] [65] . The effects of vitamin D on immune system functions in these animal models were apparently influenced by dietary calcium 38 . Vitamin D-deficient mice on low-calcium diets developed severe IBD, whereas treatment of these mice with 1,25(OH)2D3 improved IBD symptoms; even more so in mice on high-calcium diets .
In vitro studies of vitamin D and innate immunity
Vitamin D signaling through its nuclear vitamin D receptor has emerged as a key regulator of innate immunity in humans. Vitamin D has been shown to up-regulate antimicrobial peptides, such as cathelicidins and beta-defensins, as well as autophagy processes [66] [67] [68] [69] [70] . 74 . In addition, the vitamin D analogue TX 527 blocked the TNFalpha-induced activation of NF-kappaB and the nuclear translocation of the latter, together with the degradation of IKB-alpha 75 .
M a n u s c r i p t
In vitro studies of vitamin D and adaptive immunity
The effects of 1,25(OH)2D on the adaptive immune system include decreasing the numbers of Th1/Th17 CD4+ T cells and cytokines, increasing regulatory T cells and downregulating T cell-driven IgG production 7 76 77 . Furthermore, 1,25(OH)2D was shown to down-regulate IL-12 and augment IL-10 production by DCs, promoting a shift from a Th1 to a Th2 phenotype 71 . Supplementation with 140,000 IU/month vitamin D for 2 months in healthy subjects was associated with significantly increased Tregs in the peripheral circulation 78 .
Vitamin D is also involved in the regulation of many cytokines including tumour necrosis 
In vitro studies of vitamin D and mucosal barrier function
Vitamin D may also ameliorate IBD by playing a protective role in mucosal barrier homeostasis, maintaining the integrity of junction complexes and healing the colonic epithelium 63 . In cell cultures, 1,25(OH)2D3 markedly increased the expression of tight junction proteins and mRNA, and reduced mucosal permeability 83 . Vitamin D may also be involved in the physiological packaging of mucins in goblet cells 84 . Restoration of ionized calcium levels in VDR-ablated mice prevented altered mucin packaging, supporting the hypothesis that calcium is required for the physiological packaging of mucins in goblet cells.
Interestingly, mice fed a vitamin D-deficient diet showed dysregulated colonic antimicrobial activity and had ~50-fold elevated levels of bacteria in colonic tissue 85 . found that treatment with 1200 IU/day vitamin D3 for 3 months improved vitamin D status significantly compared with placebo 88 . After a follow-up of 12 months, disease relapse rates were lower in the vitamin D than in the placebo group (29% versus 13%, p = 0.06).
Clinical evidence suggesting a role of vitamin D in the pathogenesis of IBD
Ulcerative colitis
Little is known about the correlation between UC activity and vitamin D status. High disease activity was reported to be more frequent in UC patients who were than were not vitamin D-deficient (<30 ng/ml) (68%, n = 19 versus 33%, n = 14; p = 0.04) 86 . A large retrospective study found that low plasma 25(OH)D was associated with increased risks of surgery and hospitalisation 24 . A recent Chinese study of 124 patients with UC found that 25(OH)D3 levels were negatively correlated with disease severity (r = -0.371, p < 0.001) 91 .
By contrast, a large study of 504 IBD patients, including 101 with UC, reported no correlation between 25(OH)D concentrations and disease activity in UC patients 17 . Similarly, small Romanian (n = 33) and Iranian (n = 34) studies found that vitamin D levels did not correlate with disease activity, CRP concentration or erythrocyte sedimentation rate 92 93 , and a study in 21 children newly diagnosed with UC found no correlation between UC activity and vitamin D concentration 26 .
To date, no clinical trials have evaluated the effect of vitamin D supplementation on disease activity in patients with UC.
Other benefits of vitamin D supplementation
Vitamin D therapy may offer additional benefits to IBD patients, including improving bone health, reducing the risk of colorectal cancer and treating depressive symptoms 96 .
Osteoporosis
The prevalence of low bone mineral density (BMD) is greater in patients with IBD than in healthy controls 97 . It has been estimated that 22-77% of patients with IBD have osteopenia and that 12-41% have osteoporosis 4 98 . 
Prevention of colorectal carcinoma
The first study suggesting an inverse relationship between exposure to sunshine and 
Depression
Depression and anxiety are common among IBD patients 104 . Depression can can add to disability in these patients, is a risk factor for disease flare-ups and can even impair the A c c e p t e d M a n u s c r i p t effectiveness of medication 105 106 . Several studies reported that vitamin D deficiency was significantly associated with mood disorders [107] [108] [109] . Supplementation with high (3000-6000 IU/d) but not low (400-600 IU/d) doses of vitamin D seemed to ameliorate the symptoms of depression [110] [111] [112] .
A c c e p t e d M a n u s c r i p t ng/ml, and maximal genomic stability at levels of at least 36 ng/ml 114 . Two large patient cohorts showed minimal all-cause mortality rates at serum 25(OH)D concentrations of 40-48 ng/ml 115 116 . A meta-analysis of 18 RCTs assessing vitamin D supplementation for the prevention of falls and fractures found that serum 25(OH)D levels of about 30 to 44 ng/l provided optimal benefits for all investigated endpoints without increasing health risks 99 . In an interesting study from Hawaii, the highest 25(OH)D3 concentration recorded following natural exposure to ultraviolet B was 60 ng/ml 117 .
The optimal vitamin D serum concentration in IBD remains undetermined. A recent study, however, found that disease activity was the lowest at vitamin D concentrations of 50-59 ng/ml in all analysed scenarios, including in patients with UC and CD, and in analyses performed during the summer and winter seasons 25 .
Vitamin D supplementation dose
Despite considerable research, the daily intake of vitamin D needed by healthy subjects, as well as by special populations, remains undetermined 118 .
Currently, the Institute of Medicine of the National Academies has recommended an intake of 600 IU/day (800 IU/day for those >70 yrs) vitamin D for the general population, with a tolerable upper limit of 4000 IU/day for all adults and children aged >8 years 119 . By contrast, the Endocrine Society recommended a daily intake for adults of 1500-2000 IU/day
with an upper limit of 10,000 IU/day 113 Table 2 shows an overview of the relationship between vitamin D dose for at least 4 weeks and serum vitamin D concentrations in RCT for the prevention of osteoporosis 99 . A more detailed review of the largest trials is shown in Table 3 .
There The dosing schedule must also be considered. Data from clinical trials in non-IBD populations are inconsistent when comparing lower daily doses with higher weekly/monthly dosing of equipotent cumulative doses. A comparison in 40 elderly women of 400 IU twice daily (800 IU/day) with 97,333 IU of cholecalciferol every 4 months, yielding total doses of 292,000 IU in both groups, found that, after 12 months of treatment, 47% and 28%, respectively, achieved serum 25(OH)D levels of 30 ng/ml (p < 0.0001) 127 . However, compliance in these two groups was not compared. 123 . However, 62% and 25% of participants in arms B and C, respectively, did not achieve a serum 25(OH)D concentration above 30 ng/ml. A cumulative dose of 400,000 IU vitamin D2 or 220,000 IU vitamin D3 may be sufficient to achieve a serum concentration of 30 ng/ml. Interestingly, a small retrospective study of 108 veterans with IBD who received D3 were less likely than those who received D2 to use laboratory, pharmacy, radiology and fee-based services 131 .
Form of administraiton
Alternatively, vitamin D can be administered in its hydroxylated forms, as 1,25-(OH)2 D3
and 1-(OH)D3, both of which are used to treat osteoporosis, or as vitamin D analogues, such as paricalcitol, maxacalcitol, alfacalciferol, doxecalciferol and calcipotrol. Although these compounds have not been assayed in the treatment of IBD, they were shown to be effective in small open label trials in psoriasis and rheumatoid arthritis [132] [133] [134] [135] .
Heliotherapy also increases serum vitamin D concentrations. Exposure of a human body in a bathing suit to one minimal erythema dose of sunlight has been reported to be equivalent to ingesting about 10,000-25,000 IU of vitamin D 136 . In a single case report, a CD patient M a n u s c r i p t exposed to a tanning bed (UVB radiation 290-315 nm) while wearing a one-piece bathing suit for 10 minutes per day, 3 times per week for 4 weeks experienced an increase in serum 25(OH)D concentration from 7 to 32 ng/mL 137 .
Route of application
The ability to absorb vitamin D is reduced in patients with CD, due either to inflammatory involvement of the proximal part of the small intestine or to reduced circulating bile acid pool after resection of the terminal ileum. Even patients with quiescent CD showed a mean 30% decrease in their ability to absorb vitamin D2 32 . Vitamin D absorption is especially impaired in patients with previous ileal resections 35 36 138 . Treatment with oral cholecalciferol has been shown to be sufficient in patients with small or moderate resections (<300 cm), although other options, such as parenteral or oral 25-hydroxycholecalciferol supplementation, may be preferred in patients with severe short-bowel syndrome 35 .
Topical applications of vitamin D have not yet been tested in patients with IBD. In animal models of IBD, the intrarectal application of the VDR agonists (BXL-62) and 1,25(OH)VD has been shown to be effective in ameliorating experimental DSS colitis 139 .
Safety of vitamin D supplementation
Excess vitamin D can be toxic, as manifested by hypercalcemia. Excessive sunlight, however, does not lead to toxicity. A review of 25 RCTs of vitamin D supplementation for the prevention of osteoporotic fractures, falls, cardiovascular and oncologic diseases found that vitamin D supplementation was exceptionally safe 99 . Mean serum calcium levels did not correlate with oral vitamin D up to 100,000 IU/day or serum 25(OH)D concentrations up to 257 ng/ml. In all of these trials, only 24 patients experienced hypercalcemia, with most being asymptomatic and resolving after fasting. Hypocalcemia was reported in patients later diagnosed with primary hyperparathyroidism and in patients also taking calcium supplements of 1000-1500 mg per day. Of the 24 patients with hypercalcemia, 22 had serum 25(OH)D concentrations above 96 ng/ml. Even very large oral and parenteral loading doses of vitamin D3 (300,000-500,000 IU) were well tolerated and safe in small clinical trials 128 140 .
Risk analyses found that 10,000 IU/day cholecalciferol is non-toxic in healthy adults, suggesting that it is safe as an upper limit of daily intake 141 142 . However, calcium absorption improves at higher serum 25(OH)D concentrations, suggesting the need to re-evaluate calcium supplements in patients taking >2000 IU/day vitamin D 99 .
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